Sunday, September 8, 2019

Shilpa Medicare gets two USFDA observations for formulation plant in Telangana

There were no repeat observations or Data Integrity (DI) related observations, the company added.

from India Infoline News Service https://ift.tt/300V2Gh
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)